Nexxus Scotland

2009 best financial year yet for leading CRO, ClinTec International

05 February 2010

• Despite a challenging global economic climate, company reports a 45 per cent rise in global sales revenues, with innovative services developed in 17 new countries and 115 new hires during the past 12 months
• Cairo office launch cements UK CRO's reputation as major player in the Middle East and North Africa region
• ClinTec established as a key player in facilitatingrestructuring programmes, optimising R&D efforts for Global Pharma

ClinTec International, a leading full service multinational contract research organisation (CRO), has announced that it has achieved organic growth with a 45 per cent increase in global sales revenues over the last twelve months; expanded its client base signing new contracts with 11 of the world's top 25 pharmaceutical firms.

With a presence in some 40 countries around the world, ClinTec International manages clinical trials in all major therapeutic areas, including oncology, neurology, cardiovascular, respiratory as well as gastroenterology. It also has a wealth of experience in providing consultancy services in all aspects of quality assurance (QA), with ClinTec's QA team having all held senior positions within quality and manufacturing operations in the pharmaceutical, biotechnology and medical devices industries.

Dr Rabinder Buttar, the company's founder, President and CEO says: "ClinTec International is at the top of its growth metrics when compared to competitors. We have met the challenges of 2009 and indeed current projections point to the company's growth in 2010 and 2011 being sustained to the same high levels.

"Our strong financial performance, achieved during a difficult economic climate, is linked to our established track record at managing activities in a fast and flexible manner. Whilst other CROs suffered project delays or cancellations, ClinTec forged ahead developing innovative services in 17 new countries, employing 115 new staff in the process. Looking ahead to 2010 and 2011, we comfortably project a continuation of this substantial growth trend.

"The launch of our Cairo office in October was one of the high points of the year. Apart from providing our global pharmaceutical associates with access to new patient populations, ClinTec Cairo cements our reputation as the major CRO in the Middle East and North Africa (MENA) region."

ClinTec played a key role in 2009 in facilitating complex restructuring programmes for Global Pharma, who are searching for innovative ways to optimise their R&D efforts. The shift of research delivery from West to East is an area in which ClinTec is clearly able to offer a credible solution using a blend of flexible resource solutions and off-shore project delivery.

"ClinTec International excels at opening up new and emerging markets. Our unrivalled knowledge of different regulatory requirements and cultures is our strength and this means major international pharmaceutical firms know they can always turn to us,"

adds Dr Buttar.

"At ClinTec International we are committed to making a difference to human health through providing the very best quality clinical research. The dedication and support of ClinTec staff in Glasgow and all around the world has allowed us to more than meet our goals over the past year."

Released on behalf of ClinTec by Andrew Ritchie, Senior Consultant, Morhamburn T: 0131 556 0050, E: andrew@morharmburn.com.  For further information contact Bobby Bal, Senior Director Corporate Development, ClinTec International Headquarters T: 0141 226 1120, E: bbal@clintec.com.

Back